In addition, 39% within the Group I (VMPLRRDLR) and IV (VMPHRRDHR) might have achieved early optimal response and superior PFS by selecting the regimen based on the ML response models requiring a total of 10 covariates—ISS stage, type of myeloma, age, del(13q), t(11;14), diabetes, albumin level, creatinine level, urinary protein level, and ANC. The gene discussed is ALB; the disease is plasma cell myeloma.